MERCK U.S. PATENT RIGHTS
FOR PRODUCTS


In accordance with Section 287(a) of Title 35 of the United States Code, the following list identifies Merck’s rights in U.S. patents associated with the relevant product. This list may be a subset of Merck’s rights in U.S. patents directed to the relevant product.



A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | X | Y | Z



GUARDIAN®
Bovine Rotavirus-Coronavirus Vaccine, Killed Virus, Clostridium Perfringens Type C&D- Escherichia Coli Bacterin-Toxoid
U.S. Patent No. 5,916,570
INNOVAX®-ILT
FOWL LARYNGOTRACHEITIS - MAREK’S DISEASE VACCINE Serotype 3, Live Marek’s Disease Vector
U.S. Patent No. 6,875,856
U.S. Patent No. 6,984,728
Mometamax®
GENTAMICIN SULFATE, USP; MOMETASONE FUROATE MONOHYDRATE; AND CLOTRIMAZOLE, USP, OTIC SUSPENSION
U.S. Patent No. 6,127,353
Nobivac®: Canine 1-DAPPv+Cv
Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Vaccine
U.S. Patent No. 5,750,112
Nobivac®: Canine 1-DAPPvL2+Cv
Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Vaccine- Leptospira Canicola-Icterohaemorrhagiae
U.S. Patent No. 5,750,112
Nobivac®: Canine Flu H3N8
Canine influenza virus
U.S. Patent No. 7,959,929
Nobivac®: Lyme
Borrelia Burgdorferi Bacterin
U.S. Patent No. 8,137,678
U.S. Patent No. 8,414,901
Nuflor Gold™
Florfenicol
U.S. Patent No. 8,034,845
Orbax® Oral Suspension
Orbifloxacin
U.S. Patent No. 6,514,492
Posatex™ Otic Suspension
Orbifloxacin, Mometasone Furoate monohydrate and Posaconazole, Suspension
U.S. Patent No. 6,127,353
U.S. Patent No. 5,661,151
U.S. Patent No. 5,703,079
U.S. Patent No. 8,084,445
Prestige® V+ WNV with Havlogen®
ENCEPHALOMYELITIS-RHINOPNEUMONITIS-INFLUENZA-WEST NILE VIRUS VACCINE, Eastern and Western Killed Virus, Killed Flavivirus Chimera
U.S. Patent No. 8,048,459
U.S. Patent No. 8,133,712
Resflor Gold®
Florfenicol and Flunixin Meglumine
U.S. Patent No. 6,787,568
U.S. Patent No. 6,790,867
U.S. Patent No. 8,044,102
Revolor-XS
Trenbolone acetate and Estradiol
U.S. Patent No. RE39, 592
Vision® 8 Somnus with SPUR®
Clostridium Chauvoei-Septicum-Haemolyticum-Novyi-Sordellii-Perfringens Types C&D-Haemophilus Somnus Bacterin-Toxoid with SPUR
U.S. Patent No. 6,743,430
Zilmax®
Zilpaterol hydrochloride
U.S. Patent No. 5,731,028
Zuprevo™
Tildipirosin
U.S. Patent No. 6,514,946
U.S. Patent No. 8,227,429

Revised Date: 6/1/13



A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | X | Y | Z



ASMANEX® TWISTHALER®
(mometasone furoate inhalation powder)
U.S. Patent No. 5,687,710
U.S. Patent No. 5,829,434
U.S. Patent No. 6,240,918
U.S. Patent No. 6,503,537
U.S. Patent No. 8,173,172
AzaSite®
(azithromycin ophthalmic solution)
1% Sterile topical ophthalmic drops
U.S. Patent No. 6,159,458
U.S. Patent No. 6,239,113
U.S. Patent No. 6,569,443
U.S. Patent No. 6,861,411
U.S. Patent No. 7,056,893
CANCIDAS
(caspofungin acetate)
U.S. Patent No. 5,514,650
U.S. Patent No. 5,952,300
CLARINEX®
Tabets
(desloratadine) for oral use
U.S. Patent No. 6,100,274
U.S. Patent No. 7,214,683
CLARINEX®
RediTabs
(desloratadine) for oral use
U.S. Patent No. 5,607,697
U.S. Patent No. 6,100,274
U.S. Patent No. 7,214,683
U.S. Patent No. 7,618,649
CLARINEX®
Oral Solution
(desloratadine) for oral use
U.S. Patent No. 6,514,520
U.S. Patent No. 7,214,683
CLARINEX-D® 12 HOUR
Extended Release Tablets
(desloratadine/ pseudoephedrine sulfate) for oral use
U.S. Patent No. 6,100,274
U.S. Patent No. 6,709,676
U.S. Patent No. 7,214,683
U.S. Patent No. 7,618,649
CLARINEX-D® 24 HOUR
Extended Release Tablets
(desloratadine/ pseudoephedrine sulfate) for oral use
U.S. Patent No. 6,100,274
U.S. Patent No. 6,709,676
U.S. Patent No. 7,214,683
U.S. Patent No. 7,618,649
CRIXIVAN®
(INDINAVIR SULFATE)
CAPSULES
U.S. Patent No. 6,645,961
DULERA®
(mometasone furoate and formoterol fumarate dihydrate)
Inhalation Aerosol
U.S. Patent No. 6,068,832
U.S. Patent No. 7,067,502
U.S. Patent No. 7,566,705
EMEND®
(aprepitant)
Capsules 125/80 mg
U.S. Patent No. 5,719,147
U.S. Patent No. 6,096,742
EMEND®
(aprepitant)
Capsules 40mg
U.S. Patent No. 5,719,147
U.S. Patent No. 6,096,742
EMEND®
(fosaprepitant dimeglumine)
for Injection, for intravenous use
U.S. Patent No. 5,691,336
U.S. Patent No. 5,512,570
Follistim® AQ
(follitropin beta injection)
for subcutaneous or intramuscular use
U.S. Patent No. 5,767,251
U.S. Patent No. 5,929,028
Follistim® AQ Cartridge
(follitropin beta injection)
for subcutaneous use
U.S. Patent No. 5,767,251
U.S. Patent No. 5,929,028
Ganirelix Acetate Injection
ganirelix acetate
for subcutaneous use
U.S. Patent No. 5,767,082
U.S. Patent No. 6,653,286
INTEGRILIN®
(eptifibatide Injection)
U.S. Patent No. 5,686,570
U.S. Patent No. 5,747,447
U.S. Patent No. 5,756,451
INTRON® A
Interferon alfa-2b, recombinant For Injection
Powder for Injection
U.S. Patent No. 6,610,830
INTRON® A
Interferon alfa-2b, recombinant For Injection
Solution Vials for Injection
U.S. Patent No. 5,935,566
U.S. Patent No. 6,610,830
INTRON® A
Interferon alfa-2b, recombinant For Injection
Solution in Multidose Pens for Injection
U.S. Patent No. 5,935,566
U.S. Patent No. 6,610,830
INVANZ®
(ertapenem for injection)
for intravenous (IV) or intramuscular (IM) use
U.S. Patent No. 5,478,820
U.S. Patent No. 5,952,323
ISENTRESS®
(raltegravir)
Film-coated Tablets for oral use
U.S. Patent No. 7,169,780
U.S. Patent No. 7,754,731
ISENTRESS®
(raltegravir)
Chewable Tablets for oral use
U.S. Patent No. 7,169,780
U.S. Patent No. 7,754,731
JANUMET®
(sitagliptin/metformin HCl)
Tablets
U.S. Patent No. 6,699,871
U.S. Patent No. 7,326,708
U.S. Patent No. 7,125,873
JANUMET® XR
(sitagliptin and metformin HCl extended-release)
Tablets
U.S. Patent No. 6,699,871
U.S. Patent No. 7,326,708
U.S. Patent No. 7,125,873
JANUVIA®
(sitagliptin)
Tablets
U.S. Patent No. 6,699,871
U.S. Patent No. 7,326,708
JUVISYNC™
(sitagliptin and simvastatin)
Tablets
U.S. Patent No. 6,699,871
U.S. Patent No. 7,326,708
U.S. Patent No. 7,125,873
NASONEX®
(mometasone furoate monohydrate)
Nasal Spray, 50 mcg†
†calculated on the anhydrous basis
U.S. Patent No. 6,127,353
NOXAFIL®
(Posaconazole)
ORAL SUSPENSION
40 mg/mL
U.S. Patent No. 5,661,151
U.S. Patent No. 5,703,079
NuvaRing®
(etonogestrel/ethinyl estradiol)
Vaginal Ring
U.S. Patent No. 5,989,581
PegIntron®
(Peginterferon alfa-2b) Injection, Powder for Solution for Subcutaneous Use
Single-Use Vial (with 1.25 mL diluent)
U.S. Patent No. 5,951,974
U.S. Patent No. 6,180,096
U.S. Patent No. 6,610,830
PegIntron®
(Peginterferon alfa-2b) Injection, Powder for Solution for Subcutaneous Use
REDIPEN®
U.S. Patent No. 5,951,974
U.S. Patent No. 6,180,096
U.S. Patent No. 6,610,830
PROPECIA®
(finasteride)
tablets for oral use
U.S. Patent No. 5,547,957
U.S. Patent No. 5,571,817
PROVENTIL® HFA
(albuterol sulfate)
Inhalation Aerosol
U.S. Patent No. 5,605,674
SAPHRIS®
(asenapine)
sublingual tablets
U.S. Patent No. 5,763,476
U.S. Patent No. 7,741,358
SYLATRON™
(peginterferon alfa-2b) for injection, for subcutaneous use
Lyophilized powder in single-use vial
U.S. Patent No. 5,951,974
U.S. Patent No. 6,180,096
U.S. Patent No. 6,610,830
TEMODAR®
(temozolomide)
for Injection
U.S. Patent No. 6,987,108
U.S. Patent No. 7,786,118
VICTRELIS
(boceprevir)
U.S. Patent No. RE43,980
U.S. Patent No. 7,721,178
VYTORIN™
(ezetimibe/simvastatin)
Tablets
U.S. Patent No. RE42,461
ZETIA®
(ezetimibe)
Tablets
U.S. Patent No. RE42,461
U.S. Patent No. 7,030,106
ZIOPTAN™
(tafluprost ophthalmic solution) 0.0015%
U.S. Patent No. 5,886,035
ZOLINZA®
(vorinostat)
Capsules
U.S. Patent No. RE38,506

Revised Date: 6/1/13



A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | X | Y | Z



Comvax
[HAEMOPHILUS b CONJUGATE (MENINGOCOCCAL PROTEIN CONJUGATE) and HEPATITIS B (RECOMBINANT) VACCINE]
U.S. Patent No. 6,544,757
Recombivax
HEPATITIS B VACCINE (RECOMBINANT)
U.S. Patent No. 6,544,757

Revised Date: 6/1/13

TRUSTe - Click to Verify   This Web This Web Accessibility icon serves as a link to download eSSENTIAL Accessibility assistive technology software for individuals with physical disabilities. It is being featured as part of a Disability Community Involvement initiative that reflects our commitment to Diversity, Inclusion,Corporate Citizenship and Social Responsibility.